PubRank

Bruno Cassinat

Author PubWeight™ 47.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005 3.06
2 Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005 2.66
3 Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008 2.55
4 The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008 2.21
5 Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003 1.93
6 Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003 1.83
7 Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood 2004 1.70
8 Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011 1.61
9 Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003 1.57
10 High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006 1.55
11 The V617F JAK 2 mutation is not a frequent event in patients with cerebral venous thrombosis without overt chronic myeloproliferative disorder. Thromb Haemost 2008 1.38
12 Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003 1.34
13 Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 2008 1.30
14 Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica 2009 1.25
15 Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia. Br J Haematol 2010 1.01
16 Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms. Blood 2010 0.99
17 Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNA. J Clin Microbiol 2003 0.96
18 JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood 2012 0.95
19 Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One 2010 0.93
20 Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosis. J Infect Dis 2003 0.93
21 Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal 2012 0.91
22 Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group. J Clin Oncol 2012 0.87
23 Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. Br J Haematol 2008 0.86
24 The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood 2011 0.85
25 Overcoming bacterial DNA contamination in real-time PCR and RT-PCR reactions for LacZ detection in cell therapy monitoring. Mol Cell Probes 2004 0.83
26 A new variant t(6;15;17)(q25;q22;q21) in acute promyelocytic leukemia: fluorescence in situ hybridization confirmation. Cancer Genet Cytogenet 2005 0.83
27 Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer. Clin Cancer Res 2011 0.82
28 Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay. Antimicrob Agents Chemother 2005 0.81
29 Tracking the extramedullary PML-RARα-positive cell reservoirs in a preclinical model: biomarker of long-term drug efficacy. Mol Cell Probes 2012 0.81
30 Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes. Leuk Res 2012 0.80
31 Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanoma. Eur J Cancer 2007 0.80
32 Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity. Blood 2007 0.79
33 Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 2013 0.79
34 Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica 2013 0.79
35 Quantification of JAK2V617F mutation by next-generation sequencing technology. Am J Hematol 2013 0.79
36 Neurological disorders in essential thrombocythemia. Haematologica 2011 0.78
37 Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia. Blood 2002 0.77
38 Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. Blood 2005 0.76
39 Association of a single-nucleotide polymorphism in the SH2B3 gene with JAK2V617F-positive myeloproliferative neoplasms. Blood 2014 0.76
40 Auer rods and differentiation in acute promyelocytic leukemia. Br J Haematol 2008 0.75
41 TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis. Br J Haematol 2014 0.75
42 Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient. Am J Hematol 2012 0.75
43 Identification of JAK2 mutations in canine primary polycythemia. Exp Hematol 2011 0.75
44 The V617F JAK2 mutation and the increase in platelet CD36 in essential thrombocythemia are unrelated events. Eur J Haematol 2007 0.75